Revolutionizing early drug discovery for immuno-oncology and neurodegenerative disease modeling
The development of 3D cellular models of disease has enabled researchers to better recapitulate in vivo cell environments. As 3D models become more prevalent in the drug discovery industry, there is now increasing focus on maximizing the analysis of these models to better identify potential candidate molecules that can be progressed, as well as quickly identifying those that should not. In this SelectScience article, we speak with Christian Clausen, Director of Research and Development at research-based service provider Bioneer A/S, to learn about the approach the company is taking to provide 3D, high-throughput setups for biotech and pharmaceutical companies working across a number of projects, and how this technology will help immuno-oncology and neurodegenerative diseases studies in particular.